Speakers at the forum organized by the working group on drug care of the Westphalia-Lippe health insurance will discuss access to and evaluation of orphan drugs. The main question to be explored is whether the simplification of procedures granted to companies allows better access to therapies for insured patients with rare diseases. Representatives from pharmaceutical companies, statutory health insurers (SHI), the health technology assessment body G-BA, SHI-accredited physicians, and patients will participate in the discussion.
Hamm, Germany & online
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
REQUEST
an initial 10 day temporary access of APM Market Access.
